
Challenger turned down the indicative offer for its remaining shares but said it would continue discussions with Daiichi Life’s Australian unit.
Challenger’s board rejected an indicative takeover offer of A$11.80 per share from TAL Daiichi Life Australia for the remaining 79.5% of the company. It said it would engage with the Japanese insurer’s Australian unit to see whether a proposal could be reached that the board would recommend to shareholders.
Challenger said the bid was not at a level it could recommend and that there was no certainty a binding offer or transaction would result.
Bloomberg Intelligence analyst Matt Ingram said Challenger’s sum-of-the-parts value was above the bid. He wrote that a revised offer of A$12.50 to A$13 per share might be more acceptable to the board.
As of 5:20 a.m. UTC Monday, Challenger shares traded at A$11.85, down 0.59% since the previous close. Daiichi Life shares were at ¥1,830.5, up 0.63% as of 6:30 a.m. UTC.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.